| Title: | Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank population |
| Journal: | Human Genomics |
| Published: | 22 Jun 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38909264/ |
| DOI: | https://doi.org/10.1186/s40246-024-00639-z |
| URL: | https://humgenomics.biomedcentral.com/counter/pdf/10.1186/s40246-024-00639-z |
Publication 11813
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
IntroductionWe previously identified a genetic subtype (C4) of type 2 diabetes (T2D), benefitting from intensive glycemia treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Here, we characterized the population of patients that met the C4 criteria in the UKBiobank cohort.Research design and methodsUsing our polygenic score (PS), we identified C4 individuals in the UKBiobank and tested C4 status with risk of developing T2D, cardiovascular disease (CVD) outcomes, and differences in T2D medications.ResultsC4 individuals were less likely to develop T2D, were slightly older at T2D diagnosis, had lower HbA1c values, and were less likely to be prescribed T2D medications (P < .05). Genetic variants in MAS1 and IGF2R, major components of the C4 PS, were associated with fewer overall T2D prescriptions.ConclusionWe have confirmed C4 individuals are a lower risk subpopulation of patients with T2D.</p>
14 Keywords
- Aged
- Biological Specimen Banks
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Female
- Genetic Predisposition to Disease
- Glycated Hemoglobin
- Humans
- Male
- Middle Aged
- Multifactorial Inheritance
- Phenotype
- Polymorphism, Single Nucleotide
- United Kingdom
6 Authors
- Courtney Hershberger
- Arshiya Mariam
- Kevin M. Pantalone
- John B. Buse
- Alison A. Motsinger-Reif
- Daniel M. Rotroff
Enabling scientific discoveries that improve human health